2021
Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma
Gao Y, Wang M, Guo X, Hu J, Chen TM, Finn S, Lacy J, Kunstman JW, H. C, Bellin MD, Robert ME, Desir GV, Gorelick FS. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma. PLOS ONE 2021, 16: e0250539. PMID: 34587190, PMCID: PMC8480607, DOI: 10.1371/journal.pone.0250539.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Pancreatic DuctalCase-Control StudiesFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMonoamine OxidaseNeoplasm GradingPancreatic NeoplasmsPrognosisProspective StudiesRetrospective StudiesSurvival AnalysisUp-RegulationYoung AdultConceptsPlasma renalase levelsBorderline resectable PDACRenalase levelsPDAC precursor lesionsOverall survivalPDAC tissuesTumor characteristicsResectable PDACChronic pancreatitisPrecursor lesionsNormal pancreasPancreatic ductal adenocarcinoma growthAdvanced tumor characteristicsVaried clinical stagesWorse tumor characteristicsNode-positive diseasePancreatic ductal adenocarcinomaNormal pancreatic headSpindle-shaped cellsPlasma renalaseRenalase expressionUnderwent resectionAbdominal traumaPancreatic headPositive diseaseCheckpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy
Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. American Journal Of Clinical Pathology 2021, 156: 214-228. PMID: 33555016, DOI: 10.1093/ajcp/aqaa217.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overColitisFemaleHumansImmune Checkpoint InhibitorsInflammatory Bowel DiseasesMaleMiddle AgedConceptsInflammatory bowel diseaseCD8/FOXP3 ratioBiopsy specimensCPI patientsPD-1CD68 scoreFOXP3 ratioBowel diseasePD-L1Antibody-treated patientsCheckpoint inhibitor colitisPD-L1 groupInitial biopsy specimensPD-L1 expressionImmune cell reactionsColonic biopsy specimensDrug-specific differencesIBD groupCheckpoint inhibitorsChronicity scoreActivity scoreImmune phenotypeTherapeutic responseColitisShared pathophysiology
2020
Smooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases
Alpert L, Al-Sabti R, Graham RP, Pai RK, Gonzalez RS, Zhang X, Smith V, Wang HL, Westbrook L, Goldblum JR, Bakhshwin A, Shetty S, Klimstra DS, Shia J, Askan G, Robert ME, Thomas C, Frankel WL, Alsomali M, Hagen C, Mostafa ME, Feely MM, Assarzadegan N, Misdraji J, Shih AR, Agostini-Vulaj D, Meis JM, Tang S, Chatterjee D, Kang LI, Hart J, Lee SM, Smith T, Yantiss RK, Hissong EM, Gao ZH, Wu J, Resnick MB, Wu EY, Pai RK, Zhao L, Doyle LA, Chopra S, Panarelli NC, Hu S, Longacre TA, Raghavan SS, Lauwers GY, Ghayouri M, Cooper HS, Nagarathinam R, Bellizzi AM, Kakar S, Hosseini M, Rong J, Greenson JK, Lamps LW, Dong Z, Bronner MP. Smooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases. Modern Pathology 2020, 33: 1410-1419. PMID: 32051556, PMCID: PMC8405135, DOI: 10.1038/s41379-020-0492-5.Peer-Reviewed Original ResearchConceptsSmooth muscle tumorsGastrointestinal smooth muscle tumorsMuscle tumorsPrognostic featuresSmall bowelGastrointestinal tractNon-progressive tumorsProgression-free survivalSlight female predominanceDisease-related deathKaplan-Meier plotsReceiver operator characteristic analysisSoft tissue pathologistsPotential prognostic featuresOperator characteristic analysisMucosal ulcerationSerosal involvementFemale predominanceLocal recurrenceMargin statusPathologic featuresTumor sizeLarge tumorsEsophageal tumorsTumor necrosis
2019
Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor
Hwang MJ, Bryant KG, Seo JH, Liu Q, Humphrey PA, Melnick MAC, Altieri DC, Robert ME. Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor. American Journal Of Pathology 2019, 189: 1180-1189. PMID: 31079810, PMCID: PMC6560381, DOI: 10.1016/j.ajpath.2019.02.009.Peer-Reviewed Original ResearchConceptsProstate cancerTumor bulkInvasive frontHigh Gleason grade prostate cancerLocalized prostate cancerGrade prostate cancerAggressive prostate cancerCell proliferationKi-67 labelingTumor cell proliferationMetastasis predictorMetastatic diseaseDistant metastasisGleason gradeAccessible biomarkersProstate tumorsMetastatic potentialNovel markerCancerBiphasic patternProliferative rateHigh expressionOxidative metabolismReduced levelsTumors
2017
ROC-king onwards: intraepithelial lymphocyte counts, distribution & role in coeliac disease mucosal interpretation
Rostami K, Marsh M, Johnson M, Mohaghegh H, Heal C, Holmes G, Ensari A, Aldulaimi D, Bancel B, Bassotti G, Bateman A, Becheanu G, Bozzola A, Carroccio A, Catassi C, Ciacci C, Ciobanu A, Danciu M, Derakhshan M, Elli L, Ferrero S, Fiorentino M, Fiorino M, Ganji A, Ghaffarzadehgan K, Going J, Ishaq S, Mandolesi A, Mathews S, Maxim R, Mulder C, Neefjes-Borst A, Robert M, Russo I, Rostami-Nejad M, Sidoni A, Sotoudeh M, Villanacci V, Volta U, Zali M, Srivastava A. ROC-king onwards: intraepithelial lymphocyte counts, distribution & role in coeliac disease mucosal interpretation. Gut 2017, 66: 2080. PMID: 28893865, PMCID: PMC5749338, DOI: 10.1136/gutjnl-2017-314297.Peer-Reviewed Original ResearchConceptsIntraepithelial lymphocyte countsReceiver operating characteristicIntraepithelial lymphocytesCoeliac diseaseMarsh III lesionsIII lesionsHistological diagnosis of coeliac diseaseNormal controlsReceiver operating characteristic curve analysisDiagnosis of coeliac diseaseOptimal cut-off pointReceiver operating characteristic analysisOptimal cut-offCount intraepithelial lymphocytesCut-off pointCut-offHistological diagnosisLymphocyte countMulticentre studyDuodenal biopsiesAntigenic influenceCurve analysisBiopsyDose responseControl group
2001
Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study
Montgomery E, Goldblum J, Greenson J, Haber M, Lamps L, Lauwers G, Lazenby A, Lewin D, Robert M, Washington K, Zahurak M, Hart J. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study. Human Pathology 2001, 32: 379-388. PMID: 11331954, DOI: 10.1053/hupa.2001.23511.Peer-Reviewed Original ResearchConceptsHigh-grade dysplasiaLow-grade dysplasiaBarrett's esophagusInvasive carcinomaMajority diagnosisCases of HGDCases of LGDCases of BEEndoscopic biopsy specimensKaplan-Meier statisticsInitial biopsyEndoscopic surveillanceUlcerated areaGastrointestinal pathologyBiopsy specimenPredictive markerBiopsy diagnosisBiopsy specimensIntramucosal carcinomaPrecursor lesionsIND casesPowerful prognosticatorCarcinomaMorphologic evaluationUlcerated cases
2000
Evidence for the Neoplastic Transformation of Von-Meyenburg Complexes
Jain D, Sarode V, Abdul–Karim F, Homer R, Robert M. Evidence for the Neoplastic Transformation of Von-Meyenburg Complexes. The American Journal Of Surgical Pathology 2000, 24: 1131-1139. PMID: 10935654, DOI: 10.1097/00000478-200008000-00011.Peer-Reviewed Original ResearchConceptsVon Meyenburg complexesAdenomatous lesionsNeoplastic transformationTumor-like nodulesCongenital hepatic fibrosisDuctal plate malformationPattern of fibrosisBackground of fibrosisCases of cholangiocarcinomaEpithelial membrane antigenYears of ageSmall renal cystsPortal hypertensionDuctular proliferationMicronodular cirrhosisHepatic fibrosisTomographic scanHistologic examinationImmunohistochemical stainingRenal cystsCentral veinMembrane antigenCarcinoembryonic antigenCirrhosisCholangiocarcinoma
1998
Polypoid vascular malformations of the small intestine
Krinsky M, Robert M, Garcia J, Korzenik J, Topazian M. Polypoid vascular malformations of the small intestine. Gastrointestinal Endoscopy 1998, 48: 530-533. PMID: 9831847, DOI: 10.1016/s0016-5107(98)70100-2.Peer-Reviewed Original Research